Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders. Furthermore, an association with cardiovascular events is indicated. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different. Better understanding of those characteristic leads to the right choice for individual patients, resulting in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.
Keywords: biologics; inteleukin-23; interluekin-17; psoriasis; psoriatic arthritis; tumor necrosis factor-α.
Conflict of interest statement
M.K. received grants for research from Torii Pharmaceutical, Eisai, Maruho, and Novartis Pharma, and honoraria for lectures from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Kirin, Eli Lilly, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, and Janssen Pharmaceutical. Y.T. received grants for research from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Hakko Kirin, Taiho Pharmaceutical, Celgene, and Eli Lilly, and honoraria for lectures from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Kirin, Eli Lilly, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, and Janssen Pharmaceutical.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. PMID: 29271481 Free PMC article. Updated. Review.
An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.Curr Med Chem. 2015;22(16):1930-42. doi: 10.2174/0929867322666150429111804. Curr Med Chem. 2015. PMID: 25921645 Review.
Ixekizumab for the treatment of psoriasis: an update on new data since first approval.Expert Rev Clin Immunol. 2019 Feb;15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27. Expert Rev Clin Immunol. 2019. PMID: 30589394
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.J Am Acad Dermatol. 2007 Aug;57(2):269-75. doi: 10.1016/j.jaad.2006.12.003. Epub 2007 Jun 18. J Am Acad Dermatol. 2007. PMID: 17574299 Clinical Trial.
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.Cytokine. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29. Cytokine. 2018. PMID: 30172115 Review.